Much is known today about the underlying genetic and biological mechanisms in polycystic kidney disease (PKD). The Translational Polycystic Kidney Disease Center at Mayo Clinic is focused on translating these basic findings into new and better treatments for PKD patients.
The Translational PKD Center extends Mayo Clinic's strong tradition of PKD-related basic, translational and clinical research. Through the years, Mayo Clinic investigators have made many novel and important contributions to the understanding and characterization of PKD, and these findings have recently moved into preclinical and clinical trials.
Research in the center is collaborative and multidisciplinary. PKD investigators work alongside Mayo Clinic clinicians and scientists with expertise in fields such as imaging, physiology, gastroenterology, molecular biology and genomics. This team approach means that promising therapies move more quickly from the lab through clinical trials to clinical practice.
View Translational PKD Center selected publications.
Leadership and governance
- Vicente E. Torres, M.D., Ph.D.
Director, Translational PKD Center
- Peter C. Harris, Ph.D.
Associate Director, Translational PKD Center
Director, Molecular Genetics and Biomarker Core
- Stephen C. Ekker, Ph.D.
Director, Model Systems Core
- Bradley J. Erickson, M.D., Ph.D.
Director, Human Imaging Core
- Michael F. Romero, Ph.D.
Director, Pilot and Feasibility Program
Find additional information on center governance and leadership.
Three core facilities supported by the center provide both Mayo Clinic and external investigators with access to state-of-the-science technical resources and services:
Each core is also engaged in numerous developmental projects, which will lead to new and enhanced service offerings.
The Translational PKD Center's efforts are further enhanced by significant Mayo Clinic resources, including the Center for Clinical and Translational Science and many institutional core facilities.
The Translational PKD Center, established in 2010, is funded by a five-year P30 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health.